Coding Ahead
CasePilot
Medical Coding Assistant
Case2Code
Search and Code Lookup Tool
CareerCenter
Medical Coding Job Board
Log in Register free account

Need help choosing the right code?

Ask CasePilot about procedures, modifiers, bundling, and coding guidance.

Try CasePilot

Official Description

Plague vaccine, for intramuscular use

© Copyright 2026 American Medical Association. All rights reserved.

Common Language Description

The CPT® Code 90727 refers to the plague vaccine, which is administered via intramuscular injection. Vaccines are biological preparations that provide active immunity to a particular infectious disease by stimulating the body's immune system to recognize and combat pathogens, such as viruses or bacteria. Unlike immune globulins, which offer short-term, passive immunity by supplying pre-formed antibodies, vaccines work by introducing altered or inactivated forms of the pathogen, prompting the immune system to produce its own antibodies. This process not only helps in fighting off the current infection but also equips the immune system with a 'memory' of the pathogen, enabling a quicker and more effective response upon future exposures. The use of this specific code indicates the reporting of the vaccine product itself, rather than any associated services or administration procedures. It is essential for medical coders and billers to accurately document the use of this vaccine to ensure proper coding and reimbursement for immunization services provided to patients at risk of plague infection.

© Copyright 2026 Coding Ahead. All rights reserved.

1. Indications

The plague vaccine is indicated for individuals who are at risk of exposure to the plague, a serious infectious disease caused by the bacterium Yersinia pestis. This vaccine is particularly relevant for those in specific occupational settings or geographic areas where plague is endemic. The following conditions and situations may warrant the administration of the plague vaccine:

  • Occupational Exposure: Individuals working in laboratories that handle Yersinia pestis or in environments where the bacterium is present, such as certain wildlife research or public health settings.
  • Geographic Risk: Residents or travelers to regions where plague is known to occur, particularly in rural areas of the western United States, Africa, Asia, and South America.
  • Public Health Response: Individuals involved in public health initiatives during outbreaks or in response to bioterrorism threats involving plague.

2. Procedure

The administration of the plague vaccine involves several key procedural steps to ensure safety and efficacy. The following outlines the process:

  • Step 1: Prior to vaccination, the healthcare provider must assess the patient's medical history and current health status to determine eligibility for the vaccine. This includes checking for any contraindications or previous adverse reactions to vaccines.
  • Step 2: The vaccine is prepared according to the manufacturer's instructions, ensuring that it is stored and handled properly to maintain its effectiveness. This may involve checking the expiration date and ensuring the vaccine is at the correct temperature.
  • Step 3: The healthcare provider will select an appropriate site for intramuscular injection, typically the deltoid muscle in the upper arm for adults. The area is cleaned with an antiseptic to reduce the risk of infection.
  • Step 4: The vaccine is administered via intramuscular injection using a sterile syringe and needle. The provider will inject the vaccine into the muscle tissue, ensuring that the needle is inserted at the correct angle and depth.
  • Step 5: After the injection, the provider will apply gentle pressure to the injection site with a cotton ball or gauze and may apply a bandage if necessary. The patient is monitored for a short period for any immediate adverse reactions.

3. Post-Procedure

Following the administration of the plague vaccine, patients are typically advised to remain in the healthcare setting for a brief observation period to monitor for any immediate side effects, such as allergic reactions. Common post-vaccination care includes advising the patient to keep the injection site clean and dry, and to apply a cool compress if there is swelling or discomfort. Patients may experience mild side effects, such as soreness at the injection site, low-grade fever, or fatigue, which usually resolve within a few days. It is important for patients to be informed about potential side effects and when to seek medical attention. Additionally, documentation of the vaccination should be recorded in the patient's medical record, including the date of administration, vaccine lot number, and any relevant patient information for future reference.

Short Descr PLAGUE VACCINE IM
Medium Descr PLAGUE VACCINE INTRAMUSCULAR
Long Descr Plague vaccine, for intramuscular use
Status Code Excluded from Physician Fee Schedule by Regulation
Global Days XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC) 9 - Not Applicable
Multiple Procedures (51) 9 - Concept does not apply.
Bilateral Surgery (50) 9 - Concept does not apply.
Physician Supervisions 09 - Concept does not apply.
Assistant Surgeon (80, 82) 9 - Concept does not apply.
Co-Surgeons (62) 9 - Concept does not apply.
Team Surgery (66) 9 - Concept does not apply.
Diagnostic Imaging Family 99 - Concept Does Not Apply
APC Status Indicator Non-Covered Service, not paid under OPPS
Type of Service (TOS) 1 - Medical Care
Berenson-Eggers TOS (BETOS) none
MUE Not applicable/unspecified.
CCS Clinical Classification 228 - Prophylactic vaccinations and inoculations
Date
Action
Notes
2016-01-01 Deleted Deleted
2011-01-01 Changed Short description changed.
2004-01-01 Changed Code description changed.
Pre-1990 Added Code added.
Code
Description
Code
Description
Code
Description
Code
Description
CasePilot

Get instant expert-level medical coding assistance.

Ask about:
CPT Codes Guidelines Modifiers Crosswalks NCCI Edits Compliance Medicare Coverage
Example: "What is CPT code 99213?" or "Guidelines for E/M services"